Mara Goldstein
Stock Analyst at Mizuho
(2.76)
# 1,688
Out of 4,829 analysts
75
Total ratings
42.86%
Success rate
6.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $6.89 | +16.19% | 7 | Apr 9, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $26 → $32 | $5.99 | +434.22% | 2 | Jan 31, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $8.81 | +376.73% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $8.71 | +474.05% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $10.67 | +321.74% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $60.73 | +26.79% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.36 | +414.71% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.08 | +640.74% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.36 | +3,280.28% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $1.80 | +1,566.67% | 4 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $0.66 | +809.09% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $3.96 | -11.62% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.16 | +7,519.05% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $1.13 | +1,669.91% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $79.25 | +64.04% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $1.81 | +10.50% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.42 | +748.06% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.29 | +2,951.88% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $32.10 | -37.69% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $6.53 | +635.07% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.60 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $3.61 | +288.35% | 1 | Oct 12, 2017 |
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $6.89
Upside: +16.19%
Kura Oncology
Jan 31, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $5.99
Upside: +434.22%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $8.81
Upside: +376.73%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $8.71
Upside: +474.05%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $10.67
Upside: +321.74%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $60.73
Upside: +26.79%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.36
Upside: +414.71%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.08
Upside: +640.74%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.36
Upside: +3,280.28%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $1.80
Upside: +1,566.67%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $0.66
Upside: +809.09%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $3.96
Upside: -11.62%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.16
Upside: +7,519.05%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $1.13
Upside: +1,669.91%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $79.25
Upside: +64.04%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $1.81
Upside: +10.50%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.42
Upside: +748.06%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.29
Upside: +2,951.88%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $32.10
Upside: -37.69%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $6.53
Upside: +635.07%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $19.60
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $3.61
Upside: +288.35%